JP2021519295A5 - - Google Patents

Info

Publication number
JP2021519295A5
JP2021519295A5 JP2020551797A JP2020551797A JP2021519295A5 JP 2021519295 A5 JP2021519295 A5 JP 2021519295A5 JP 2020551797 A JP2020551797 A JP 2020551797A JP 2020551797 A JP2020551797 A JP 2020551797A JP 2021519295 A5 JP2021519295 A5 JP 2021519295A5
Authority
JP
Japan
Prior art keywords
less
milligrams
antibody
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020551797A
Other languages
English (en)
Japanese (ja)
Other versions
JP7526099B2 (ja
JP2021519295A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000314 external-priority patent/WO2019186273A1/en
Publication of JP2021519295A publication Critical patent/JP2021519295A/ja
Publication of JP2021519295A5 publication Critical patent/JP2021519295A5/ja
Priority to JP2023218600A priority Critical patent/JP2024045121A/ja
Application granted granted Critical
Publication of JP7526099B2 publication Critical patent/JP7526099B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551797A 2018-03-28 2019-03-27 抗cd38抗体の皮下投薬 Active JP7526099B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023218600A JP2024045121A (ja) 2018-03-28 2023-12-25 抗cd38抗体の皮下投薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649489P 2018-03-28 2018-03-28
US62/649,489 2018-03-28
PCT/IB2019/000314 WO2019186273A1 (en) 2018-03-28 2019-03-27 Subcutaneous dosing of anti-cd38 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023218600A Division JP2024045121A (ja) 2018-03-28 2023-12-25 抗cd38抗体の皮下投薬

Publications (3)

Publication Number Publication Date
JP2021519295A JP2021519295A (ja) 2021-08-10
JP2021519295A5 true JP2021519295A5 (cg-RX-API-DMAC7.html) 2022-03-23
JP7526099B2 JP7526099B2 (ja) 2024-07-31

Family

ID=66647425

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551797A Active JP7526099B2 (ja) 2018-03-28 2019-03-27 抗cd38抗体の皮下投薬
JP2023218600A Pending JP2024045121A (ja) 2018-03-28 2023-12-25 抗cd38抗体の皮下投薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023218600A Pending JP2024045121A (ja) 2018-03-28 2023-12-25 抗cd38抗体の皮下投薬

Country Status (12)

Country Link
US (1) US20210047427A1 (cg-RX-API-DMAC7.html)
EP (1) EP3774915A1 (cg-RX-API-DMAC7.html)
JP (2) JP7526099B2 (cg-RX-API-DMAC7.html)
KR (2) KR20210002499A (cg-RX-API-DMAC7.html)
CN (1) CN112154156A (cg-RX-API-DMAC7.html)
AU (2) AU2019244478B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019710A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095086A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020013252A2 (cg-RX-API-DMAC7.html)
MX (1) MX2020010144A (cg-RX-API-DMAC7.html)
TW (2) TW202504926A (cg-RX-API-DMAC7.html)
WO (1) WO2019186273A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体の皮下製剤及びその使用
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CN112513087B (zh) * 2018-09-11 2023-01-24 江苏恒瑞医药股份有限公司 抗cd38抗体、其抗原结合片段及医药用途
MA53920A (fr) * 2018-10-17 2021-09-15 Janssen Biotech Inc Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
AU2020397170A1 (en) * 2019-12-05 2022-07-21 Sanofi-Aventis U.S. Llc Formulations of anti-CD38 antibodies for subcutaneous administration
BR112022023137A2 (pt) * 2020-05-15 2023-02-07 Takeda Pharmaceuticals Co Administração de inibidor de enzima de ativação de sumo e anticorpos anti-cd38
EP4376869A1 (en) 2021-07-28 2024-06-05 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
US20240400711A1 (en) * 2021-09-23 2024-12-05 Sound Biopharmaceuticals Co. Ltd. Cd38 monoclonal antibody and application thereof
US20260217850A1 (en) * 2022-12-21 2026-07-30 Sound Biopharmaceuticals Co. Ltd. Cd38 monoclonal antibody and use thereof
KR20250135226A (ko) 2023-01-06 2025-09-12 다케다 야쿠힌 고교 가부시키가이샤 자가면역 질환의 치료를 위한 항-cd38 항체
WO2025193746A1 (en) 2024-03-12 2025-09-18 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia
WO2025235919A1 (en) 2024-05-09 2025-11-13 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IT1320715B1 (it) 2000-10-19 2003-12-10 Cselt Centro Studi Lab Telecom Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
EP2551282A3 (en) * 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
MX373301B (es) 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
US10533057B2 (en) 2015-05-13 2020-01-14 Morphosys Ag Treatment for multiple myeloma (MM)
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体の皮下製剤及びその使用
MA45674A (fr) * 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes

Similar Documents

Publication Publication Date Title
WO2019186273A4 (en) Subcutaneous dosing of anti-cd38 antibodies
JP2024045121A5 (cg-RX-API-DMAC7.html)
JP2025016606A5 (cg-RX-API-DMAC7.html)
JP2024167313A5 (cg-RX-API-DMAC7.html)
JP2020528768A5 (cg-RX-API-DMAC7.html)
JP2021528423A5 (cg-RX-API-DMAC7.html)
JP2021524256A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
CN108473578A (zh) 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合
JP2020002172A5 (cg-RX-API-DMAC7.html)
JP2021510736A5 (cg-RX-API-DMAC7.html)
JP2009519257A5 (cg-RX-API-DMAC7.html)
AU2021221287B2 (en) Engineered anti-IL-2 antibodies
JP2021512107A5 (cg-RX-API-DMAC7.html)
JP2015500822A5 (cg-RX-API-DMAC7.html)
JP2023542291A5 (cg-RX-API-DMAC7.html)
JP2022512851A5 (cg-RX-API-DMAC7.html)
JP2021510523A5 (cg-RX-API-DMAC7.html)
JP2024516698A5 (cg-RX-API-DMAC7.html)
JP2023133432A5 (cg-RX-API-DMAC7.html)
WO2013171287A1 (en) Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
AU2016260895A1 (en) Treatment for multiple myeloma (MM)
US20240366597A1 (en) Cancer treatment combinations
JP2018533569A5 (cg-RX-API-DMAC7.html)
JP2021506817A5 (cg-RX-API-DMAC7.html)